Clinical trial NCT04864054: T-Cell Therapy (ECT204) in Adults With Advanced HCC
Official title: An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Hepatocellular Carcinoma
Liver Cancer, Adult
Liver Neoplasm
Metastatic Liver Cancer
Keywords: Hepatocellular Carcinoma
Advanced HCC
Late-Stage HCC
Liver Cancer
Liver Neoplasm
Metastatic Liver Cancer
Metastatic HCC
T-cell therapy
Immunotherapy
HCC
Lead sponsor: Eureka Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2021-04-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: In Phase 2 (expansion phase) of the Phase I/II study, subjects will be assigned in a parallel, non-randomized manner to one of two expansion cohorts: Arm A or Arm B.
Primary purpose: TREATMENT

Brief summary: This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents.

Phase I has concluded and a Recommended Phase II Dose (RP2D) has been determined. We are now conducting Phase II to further confirm the safety profile of ECT204 and evaluate its efficacy.

Detailed description: This is an open-label, dose escalation, multi-center, Phase I/II clinical trial. The purpose of this study is to evaluate an investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC). In this study, a patient's T cells are collected and genetically modified to express Eureka's proprietary anti-GPC3 ARTEMIS T cell receptors (AbTCR). These modified T cells are then reintroduced into the patient to specifically seek out and destroy GPC3-expressing cancer cells.

Phase 1 (Dose Escalation Phase): Completed; RP2D of ECT204 was determined.

Phase 2 (Expansion Phase): The expansion phase includes 2 study arms.

Arm A: Subjects will receive ECT204 as monotherapy

Arm B: Subjects will receive pre-treatment with regorafenib (STIVARGA®) before ECT204 administration.

The active assessment period of the study will continue for 2 years. Subjects will be followed for assessment of treatment safety and overall survival during Long Term Follow-Up (LTFU; year 2 -15).

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed HCC, which is unresectable, recurrent and/or metastatic.
* GPC3-positive expression in HCC tumor cells confirmed by immunohistochemistry (IHC). To be eligible for Phase 2 (expansion phase) of the study, the subject's tumor biopsy sample (resection or needle core sample) must demonstrate that more than 50% of tumor cells exhibit at least 3+ GPC3 expression intensity.
* Must have failed, or not tolerated, at least two (2) different anti-HCC systemic agents.
* Life expectancy of at least 4 months per the Investigator's opinion.
* Karnofsky Performance Scale of 70 or higher.
* Measurable disease by RECIST v1.1. Previously treated lesions are allowed as long as there is a new confirmed measurable component.
* Child-Pugh score of A6 or better.
* Adequate organ function.

Exclusion Criteria:

* Pre-existing illness (e.g., symptomatic congestive heart failure) that would limit compliance with study requirements.
* Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled.
* Active malignancy (other than HCC), with the exception of cholangiocarcinoma (CCA) or any malignancy without any organ involvement and with an expected survival ≥ 3 years without any treatment (exception: hormone/androgen- deprivation therapy).
* Currently receiving or ending (\< 14 days from date of consent) liver tumor-directed therapy (e.g., radiation, ablation, embolization), or hepatic surgery.
* Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study.
* Active autoimmune disease requiring therapy.
* Compromised circulation in the main portal vein, hepatic vein, or vena cava due to obstruction.
* History of organ transplant.
* Advanced HCC involving greater than half (50%) of the liver.

Primary outcomes:
measure: To assess the safety and tolerability of ECT204 in adult subjects with advanced HCC
timeFrame: 28 days
measure: To determine the Recommended Phase II Dose (RP2D) of ECT204 (Concluded During Phase 1 of the study)
timeFrame: 21 months - This outcome was completed on December 20, 2023
Secondary outcomes:
measure: To assess the efficacy of ECT204 in adult subjects with advanced HCC using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (RECIST v1.1) as the primary criterion.
timeFrame: Up to 2 years
measure: To characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204, in our study subject population
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope
state: California
city: Westwood
country: United States
facility: Kansas University Medical Center, Principal Investigator:
state: Kansas
city: Buffalo
country: United States
facility: Roswell Park Comprehensive Cancer Center
state: New York
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Center, University of Washington
state: Washington
city: Taipei
country: Taiwan
facility: National Taiwan University Cancer Center
Study officials:
affiliation: Eureka Therapeutics Inc.
name: Pei Wang, PhD
role: STUDY_DIRECTOR
References: